SMTL ID : 8yki.2 (1 other biounit)

FGFR-1 in complex with ligand tasurgratinib

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.79 Å

Oligo State

monomer

Ligands

1 x 01: Tasurgratinib

01.1: 17 residues within 4Å: Chain A: L.27, V.35, A.55, K.57, E.74, M.78, V.104, E.105, Y.106, A.107, S.108, K.109, G.110, L.173, A.183, D.184, F.185 12 PLIP interactions: 12 interactions with chain A Hydrophobic interactions: A:L.27, A:A.55, A:K.57, A:V.104, A:V.104, A:L.173 Hydrogen bonds: A:E.74, A:E.74, A:A.107, A:A.107, A:D.184 pi-Cation interactions: A:K.57

1 x CL: CHLORIDE ION(Non-functional Binders)

CL.2: 1 residues within 4Å: Chain A: W.14 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Kawano, S. et al., Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion. Anticancer Res. (2024)

Release Date

2024-06-12

Peptides

Fibroblast growth factor receptor 1: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

Fibroblast growth factor receptor 1

Related Entries With Identical Sequence